In the fifth edition of our special newsletter, SCHLAGLICHT – New Drugs for Dementia, Anne Keefer, a research associate at digiDEM Bayern, discusses the publication by an international group of researchers led by Prof. Alberto J. Espay of the University of Cincinnati. In the article titled "Recalibrating the Risk-Benefit Profiles of Lecanemab..."
In the fourth edition of our new special newsletter SCHLAGLICHT – New Drugs for Dementia, Florian Weidinger, research associate at digiDEM Bayern, deals with the publication "The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer’s disease: an EADC-EC viewpoint" by the research team led by Professor Linus Jönsson from the Karolinska Institutet in Sweden. In the journal The Lancet…
In the third issue of our new special newsletter "SCHLAGLICHT – New Medications for Dementia," Dr. Nikolas Dietzel, a research associate at digiDEM Bayern, discusses the publication by scientists from Europe, the USA, and Australia, led by Professor Poul F. Høilund-Carlsen from Odense University Hospital in Denmark. In the article titled "Donanemab, another anti-Alzheimer’s…"
